Afya (NASDAQ:AFYA) Rating Increased to Overweight at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. has upgraded Afya's rating from "neutral" to "overweight", setting a new price target of $24.50, which indicates a potential upside of 62.90% from its previous close.
• A range of analysts have recently given varying ratings on Afya, with three rating it as a Buy and others providing Hold and Sell ratings, leading to an average rating of "Hold" with a consensus target price of $18.20.
• Afya operates as a medical education group in Brazil, providing various educational products and services, and has recently seen increased investments from large institutional investors.

Afya (NASDAQ:AFYA - Get Free Report) was upgraded by research analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a $24.50 price objective on the stock, up from their prior price objective of $23.50. JPMorgan Chase & Co.'s target price suggests a potential upside of 62.90% from the stock's previous close.

AFYA has been the topic of several other reports. Morgan Stanley set a $17.50 price target on Afya and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Zacks Research upgraded Afya to a "hold" rating in a research note on Friday, August 8th. Wall Street Zen upgraded Afya from a "hold" rating to a "buy" rating in a research note on Friday, August 22nd. UBS Group upgraded Afya from a "neutral" rating to a "buy" rating and lowered their price objective for the company from $19.50 to $19.00 in a research note on Monday. Finally, Citigroup upgraded Afya from a "sell" rating to a "neutral" rating and lowered their price objective for the company from $16.00 to $14.00 in a research note on Tuesday, July 29th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $18.20.

Afya Price Performance

Shares of AFYA stock opened at $15.04 on Monday. The firm has a market cap of $1.41 billion, a P/E ratio of 11.39, a P/E/G ratio of 0.53 and a beta of 0.56. Afya has a fifty-two week low of $13.47 and a fifty-two week high of $19.90. The business's 50 day moving average price is $15.28 and its 200-day moving average price is $17.03. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.94 and a current ratio of 0.94.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AFYA. Carrera Capital Advisors purchased a new position in shares of Afya during the 2nd quarter valued at about $1,750,000. Wellington Management Group LLP bought a new position in shares of Afya in the fourth quarter worth about $829,000. Jump Financial LLC bought a new position in shares of Afya in the second quarter worth about $731,000. Lazard Asset Management LLC boosted its stake in shares of Afya by 54.3% in the fourth quarter. Lazard Asset Management LLC now owns 97,313 shares of the company's stock worth $1,545,000 after acquiring an additional 34,246 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Afya by 167.3% in the first quarter. Goldman Sachs Group Inc. now owns 45,093 shares of the company's stock worth $809,000 after acquiring an additional 28,226 shares during the period. 88.02% of the stock is owned by hedge funds and other institutional investors.

Afya Company Profile

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.